Floatz logo

BMS-986345

Indolent Non-Hodgkin Lymphoma

SecuraBioPhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
81/ 100

Competitive context

16 Active assets in the Indolent Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BB
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Fox Chase Cancer Center
Phase 3BB
FILGRASTIM
Department of Medical Services Ministry of Public Health of Thailand
Phase 4BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BB

View all 34 →

Same molecule, other indications

BMS-986345 is also rated in:

Chronic Lymphocytic LeukemiaDormant
B
Indicative ·
58 / 100
View asset →
Follicular LymphomaDormant
B
Indicative ·
56 / 100
View asset →
Relapsed/Refractory T-cell LymphomasDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →